

**DICHIARAZIONE DI ACCETTAZIONE DELLA CANDIDATURA ALLA CARICA DI  
AMMINISTRATORE DI GENENTA SCIENCE S.P.A.**

Il sottoscritto Pierluigi Paracchi, nato a Milano il 22 maggio 1973, residente a Milano, Piazza Maria Adelaide di Savoia 1, codice fiscale PRCPLG73E22F205F, ,

**premessò che**

- è stato/a designato/a quale candidato/a alla carica di Amministratore di Genenta Science S.p.A., con sede legale in Milano, Via dell'Annunciata 31, codice fiscale e numero di iscrizione al Registro delle Imprese di Milano Monza Brianza Lodi 08738490963 (la "Società") ai fini della nomina del Consiglio di Amministrazione della Società prevista al punto 2 dell'ordine del giorno della Assemblea Ordinaria e Straordinaria degli Azionisti, convocata in sede ordinaria e straordinaria, esclusivamente in teleconferenza, in prima convocazione per il giorno 29 giugno 2026 alle ore 17:00 e, occorrendo, in seconda convocazione per il giorno 30 giugno 2026 alle ore 17:30;

- è a conoscenza dei requisiti previsti dalla vigente normativa e dalle disposizioni dello statuto sociale della Società per l'assunzione della carica di Amministratore;

**tutto ciò premesso, dichiara sotto la propria responsabilità:**

- di accettare la candidatura e l'eventuale nomina alla carica di Amministratore e Presidente del Consiglio di Amministrazione della Società;

- l'inesistenza di cause di ineleggibilità e di incompatibilità con la carica di Amministratore ai sensi di legge e dello statuto sociale;

- di possedere tutti i requisiti prescritti dalla normativa vigente per ricoprire la carica di Amministratore;

- l'assenza di cause di ineleggibilità previste dal Codice Civile e di interdizioni dall'ufficio di amministratore adottate nei propri confronti in uno Stato membro dell'Unione Europea.

- di autorizzare fin d'ora la pubblicazione del *curriculum vitae*, atto a fornire esauriente informativa sull'esperienza professionale e caratteristiche personali;

Si allegano: *curriculum vitae*; documento di identità.

Milano, 4 giugno 2026

Firma: Pierluigi Paracchi

# PIERLUIGI PARACCHI

PIERLUIGI.PARACCHI@GENENTA.COM  
PIERLUIGI.PARACCHI@PRAEXIDIA.COM

---

## CAREER OVERVIEW

---

<b>Italian Academy   Columbia University</b> New York, New York, United States	<b>GUARANTOR</b> <a href="https://italianacademy.columbia.edu">https://italianacademy.columbia.edu</a> The Academy is a premier global center for research in the humanities and sciences, founded in 1991 on the basis of an agreement between Columbia University and the Republic of Italy. Its chief commitment is to promote groundbreaking cross-disciplinary work while addressing international social issues.	March 2026 - Present
<b>Fondazione Praexidia,</b> Milano (Italy)	<b>CHAIRMAN</b> The Praexidia Foundation aims to promote recognition and awareness of the importance of strategic industrial sectors for Italy's national security, technological innovation, and competitiveness, with particular reference to the sectors protected under Italian Golden Power regulations. The Foundation serves as a reference point for the protection and promotion of the most critical industrial supply chains — from defense to aerospace, from dual-use technologies to strategic infrastructure, from energy to biotechnology. Special attention is devoted to small and medium-capitalization enterprises (SMCs – small-mid caps), which form the backbone of these sectors, supporting initiatives designed to strengthen the country's competitiveness and safeguard its technological assets.	2025 - Present
<b>Genenta,</b> Milano (Italy)	<b>CHAIRMAN, CO-FOUNDER AND CEO</b> Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN), is a strategic industrial consolidator focused on biotech, defense, aerospace, and national-security-related technologies.	2014 - Present
<b>Ministero degli Affari Esteri e della Cooperazione</b>	<b>MODERATOR OF THE WORKING TABLE FOR THE INTERNATIONALIZATION OF BIOTECHNOLOGY SECTOR</b> Present The establishment of the round table, which is called upon to formulate strategies and recommendations on the internationalisation of players active in the field of biotechnology in order to strengthen the entire national sector, “reflects the attention that the Italian government attaches to the international development of innovative supply chains and emerging technologies, within the framework of Growth Diplomacy”, according to the vice premier and Foreign Minister Antonio Tajani. The table will be attended by representatives of institutions, research centres, companies, trade associations and the financial world. Among others, as moderator, Pierluigi Paracchi, CEO of Genenta and member of the Executive Committee of Federchimica-Assobiotec; Pierluigi Petrone, Vice President of Farmaindustria; Giovanni Caforio, Executive Chairman of Bristol Myers Squibb; Maria Cristina Porta, General Director of the ENEA Tech and	2024 - Present

Biomedical Foundation; Giuseppe Gigli, Director of the CNR-Nanotec Institute of Nanotechnology; Rino Rappuoli, Scientific Director of Fondazione Biotechnopolo di Siena; Gianmario Verona, President of Human Technopole. Representatives of the Italian Ministry of Enterprises and Made in Italy, the Italian Ministry of University and Research and the ICE Agency will also be attending.

**Assolombarda**  
Milano (Italy)

**BOARD MEMBER**

2025 - Present

Life Sciences Advisory Board.

**InnovUp - Italian  
Innovation & Startup  
Ecosystem**

**BOARD MEMBER**

2018 - Present

Italia Startup is the non-profit association that represents, supports, and gives voice to the Italian innovation ecosystem. Founded in 2012, in response to the government's call to the Italian innovation actors, the association brings together among others entrepreneurs, incubators, investors, startupper, public entities, and private companies.

**Assobiotech**

**EXECUTIVE COMMITTEE MEMBER**

2016 - 2026

Assobiotech, the Italian Association for the Development of Biotechnology, was born to foster, support and defend the development of biotechnology in all its various application fields. Set up in 1986 within the Italian Federation of the Chemical Industry (Federchimica), Assobiotech represents companies and science & technology parks operating in Italy and involved in several sectors of life sciences.

**IAB Italian Angels for  
Biotech**

**BOARD MEMBER**

2015 - Present

IAB is an association made by a group of people with significant experience in Life Sciences. IAB goal is to identify and nurture top talent entrepreneurs in the Life Sciences sector. IAB leads equity investments to help ideas and start-ups to reach key objectives.

Members include successful entrepreneurs and investors, prominent executives, advisors, physicians and scientists. Most IAB members have been also founders and/or senior executives in companies within the healthcare space.

[www.ItalianAB.it](http://www.ItalianAB.it)

**Altheia Science**  
Milano (Italy) / New York (NY)

**CO-FOUNDER AND BOARD MEMBER**

2017 - February 2026

Altheia Science is a pioneering start-up founded by two world renowned Italian scientists, Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT. Altheia Science's pipeline exploits pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments. This can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients' hematopoietic stem cells. Altheia Science's approach intends to drastically modify the natural history of diseases with high clinical impact in autoimmunity and cancer by modulating PD-L1 expression, achieving tangible and durable benefit for each patient.

<b>Axon Partners Group</b> Madrid area (Spain)	<p><b>CO-FOUNDER &amp; INVESTMENT COMMITTEE MEMBER - VC FUND OF FUNDS</b> 2007 - 2025</p> <p>Axon Partners Group (Axon) is a global Investment, Alternative Asset Manager and Advisory firm with presence and experience worldwide. Axon's reputation for excellence is well known among investors and clients all around the world. Axon was founded by entrepreneurs with extensive financial and business development experience. Axon has grown to create a team of more than 80 experts in our offices in Madrid, Istanbul, Mexico City, Bogotá, Riyadh and Seville.</p>
<b>Lipogems international</b>	<p><b>CHAIRMAN OF THE BOARD</b> 2020 - 2025</p> <p>Medical device for processing adipose tissue.</p>
<b>American Chamber of Commerce</b>	<p><b>COORDINATOR - BOWLING GREEN BULL INITIATIVE</b> 2022 - 2024</p> <p>Bowling Green Bull (BGB) is an initiative to connect Italian companies, entrepreneurs and top managers aiming for international growth and expansion in their interactions with U.S. financial markets and investors. The initiative, promoted by the American Chamber of Commerce in Italy (AmCham Italy) and Genenta Science SpA (Nasdaq: GNTA), includes Bank of America (NYSE: BAC), Brunswick Group, Cleary Gottlieb Steen &amp; Hamilton LLP, Docebo (Nasdaq: DCBO), D-Orbit, Equita Capital SGR, Kairos Partners SGR, Nasdaq (Nasdaq: NDAQ), Petrone Group and other Italian companies listed on U.S. stock markets.</p>
<b>EconomyUp</b>	<p><b>CONTRIBUTOR</b> 2013 - 2020</p> <p>"Three-Comma Club" Blog</p>
<b>Università Cattolica del Sacro Cuore - ConLab</b> Milano (Italy)	<p><b>MEMBER OF THE EVALUATION COMMISSION</b> 2015 - 2020</p> <p>ConLab is the Catholic University coworking space.</p>
<b>Confindustria</b> Milano (Italy)	<p><b>LIFE SCIENCES TECHNICAL GROUP MEMBER</b> 2016 - 2020</p> <p>Confindustria is the main association representing manufacturing and service companies in Italy, with a voluntary membership of more than 150,000 companies of all sizes, employing a total of 5,434,352 people.</p>
<b>Cluster Life Science Lombardia</b>	<p><b>START-UP DELEGATE</b> 2016 - 2020</p> <p>The cluster aims to favor the aggregation of resources. We bring together industry, academia and clinical community to support the advance of life sciences in Lombardy.</p>
<b>Performedia S.r.l.</b> Milano (Italy)	<p><b>BOARD DIRECTOR</b> 2014 - 2015</p> <p>Performedia has great experience in Digital ADV oriented to results. Performedia works to optimize every detail of the Digital Media Mix (Credibility, Reputation, Product) contextualizing it in the market's scenario (Competitors) and taking the flows of Web interactions into consideration.</p> <p>Performedia is part of Digitouch Group, the independent leader in digital marketing in Italy (listed on AIM).</p>

<b>Performedia S.r.l.</b> Milano (Italy)	<p><b>BOARD DIRECTOR</b> <span style="float: right;">2013 - 2014</span></p> <p>Performedia has great experience in Digital ADV oriented to results. Performedia works to optimize every detail of the Digital Media Mix (Credibility, Reputation, Product) contextualizing it in the market's scenario (Competitors) and taking the flows of Web interactions into consideration.</p> <p>September 9, 2014. Digitouch announced the acquisition of Performedia. Digitouch is the italian independent leader in media and digital communications.</p>
<b>Digital360</b> Milano (Italy)	<p><b>BUY SIDE ADVISOR</b> <span style="float: right;">2014 - 2015</span></p> <p>Digital360 is an Italian leader in B2B editorial contents, marketing and communication services, lead generation, events and webinars, advisory, advocacy e coaching, in the Digital Transformation and Entrepreneurial Innovation.</p>
<b>Sofinnova Partners</b>	<p><b>VENTURE CONSULTANT</b> <span style="float: right;">2011 - 2014</span></p> <p>Sofinnova Partners is an independent venture capital firm based in Paris, France. For 40 years, the firm has backed nearly 500 companies at different stages of their development – pure creations, spin-offs, as well as turnaround situations – and worked alongside Europe's key entrepreneurs in the Life Sciences industry. With €1.3 billion of funds under management, Sofinnova Partners has created market leaders with its experienced team and hands-on approach in building portfolio companies through to exit.</p>
<b>EOS Ethical Oncology Science</b>	<p><b>INVESTOR AND BOARD DIRECTOR</b> <span style="float: right;">2008 - 2013</span></p> <p>Pharma Company specialized in oncology, drug development. Shareholders as Investors: Quantica SGR (IT), Sofinnova Partners (F) and Aescap Ventures (NL). Industrial Partner: Servier, the first French independent pharmaceutical group (EU rights - 2012: upfront 45M€ + milestones and royalties).</p> <p>EOS was acquired in November 2013: 200M\$ upfront + 220M\$ milestones.</p>
<b>Pharmeste</b>	<p><b>BOARD DIRECTOR</b> <span style="float: right;">2007 - 2013</span></p> <p>Pharma Company specialized in drug discovery, pain. Shareholders as main Investors: Zambon Group, MPS Ventures, MPH Ventures.</p>
<b>Simple Agency</b>	<p><b>SELL SIDE ADVISOR</b> <span style="float: right;">2011 - 2013</span></p> <p>Simple Agency is a new generation digital marketing services provider that aims to simplify the approach to marketing and advertising in the interactive industry. Based on an innovative business model integrating marketing, media, creativity and technology, Simple Agency is focused on digital strategy, automated and real time display advertising, search and mobile marketing, attribution modelling and conversion funnel optimisation, creative production and web development.</p> <p>July 30, 2013. Aegis Media (Dentsu Group) announced the acquisition of a majority stake in Simple Agency. Aegis Media is the world's leading focused media and digital communications specialist.</p>

<p><b>Travellution</b> Paris, Incubateurs Nouveaux Medias</p>	<p><b>ADVISORY BOARD MEMBER</b> 2012 - 2013 Travel Social Network. Investors: OSEO, a French quasi-governmental Agency, Business Angels.</p>
<p><b>Axòn Capital SGEGR SA</b></p>	<p><b>FOUNDER - INVESTMENT ADVISOR</b> 2006 - 2012 Private Equity Company, closed-end funds active in EU, LatAm and India. Axòn Capital manages early to growth capital funds of over 130 Million USD in technology and innovation, supported by prestigious investors from all over the world. Axòn has a global footprint, with offices in Madrid, Miami, Bogotá and Bangalore (Associate office) and investors and clients in Europe, Latin America, the Middle East, Africa and India.</p>
<p><b>GreenFluff</b></p>	<p><b>BOARD DIRECTOR</b> 2006 - 2012 Green and Cleantech Company. Industrial shareholder: Boldrocchi Group.</p>
<p><b>European Commission</b></p>	<p><b>INDEPENDENT EXPERT OF THE EUROPEAN COMMISSION'S 7TH FRAMEWORK PROGRAM FOR RESEARCH</b> 2010 - 2012 Independent Expert for Evaluation of research grant proposals within the 7th Framework Program (FP7) for Research.</p>
<p><b>Quantica SGR</b></p>	<p><b>FOUNDER AND CEO</b> 2002 - 2011 Venture and Expansion Capital Company. The leading Italian VC firm (2002-2011) with about 100M€ under management. The first VC company specialized in investments stemming from the Italian scientific research. In 2008 Quantica was awarded by the "Private Equity of the Year – Premio Demattè" AIFI for the best early stage exit. EOS - Ethical Oncology Science and Banzai Group are part of the Principia I Fund portfolio.</p>
<p><b>Start Up School - Augmendy</b></p>	<p><b>MENTOR</b> 2011 - 2011 Start Up School.</p>
<p><b>OneDegree - Banzai Group</b></p>	<p><b>BOARD DIRECTOR</b> 2009 - 2010 Smart Search Engine: yourank.it.com OneDegree is part of Banzai Group, Italian leader as Internet player, revenues around 100 million Euros; EPrice.it and SaldiPrivati.it are part of Banzai Group.</p>
<p><b>NewCorTec</b> Roma (Italy)</p>	<p><b>BOARD DIRECTOR</b> 2008 - 2008 Biomedical Company, Artificial Heart (V.A.D.).</p>
<p><b>Jobadvisor</b></p>	<p><b>FOUNDER</b> 1998 - 2004 Italian Career Book Leader (more than 100.000 copies), one of the first Italian e-recruiting website.</p>
<p><b>Il Sole 24 Ore</b></p>	<p><b>COMMENTATOR</b> 2001 - 2002 Commentator on Hi-tech and Biotech companies listed on Nasdaq and NYSE.</p>

<b>Euroconsult SGR</b>	<b>CHIEF INVESTMENT MANAGER</b> Independent Asset Management Company, open-end funds, top performer in 1999 and 2000 as “Global Equity Fund” and as “Global Equity/Bond Fund”. In 2000, the Global Equity Fund was the top performer year on year of its category with more than 100% return.	1999 - 2002
<b>Albertini SIM</b>	<b>EQUITY ASSET MANAGER - PRIVATE BANKING</b> Private Banking boutique. As shareholder Società Generale then Dresdner Bank.	1999 - 1999
<b>Bayerische Landesbank</b>	<b>PROPRIETARY TRADER AND ASSET MANAGER (OPTIONS AND BONDS)</b> Leading German Bank, the Bank of the Bavarian Region. One of the three banks in EU with triple A by the top three international rating companies.	1998 - 1998
<b>Banque Bruxelles Lambert</b>	<b>EQUITY, BOND AND FUTURE PROPRIETARY TRADER</b> The second Belgian Bank, then part of ING Group, with branches also in Asia and USA.	1997 - 1997

## EDUCATION

---

<b>Degree in Economy</b> Milano (Italy)	<b>UNIVERSITÀ CATTOLICA DEL SACRO CUORE</b>	1992 - 1996
--	---	-------------